2012 Annual Report  CONSOLIDATED BALANCE SHEETS  Dollars in Millions, Except Share and Per Share Data  December 31,  ASSETS  2012 2011 Current Assets:  Cash and cash equivalents  $   1,656  $  5,776  Marketable securities   1,173   2,957  Receivables   3,083   3,743  Inventories   1,657   1,384  Deferred income taxes   1,597   1,200  Prepaid expenses and other   355   258  Total Current Assets   9,521   15,318  Property, plant and equipment   5,333   4,521  Goodwill   7,635   5,586  Other intangible assets   8,778   3,124  Deferred income taxes   203   688  Marketable securities   3,523   2,909  Other assets   904   824  Total Assets  $   35,897  $  32,970  LIABILITIES Current Liabilities:  Short-term borrowings and current portion of long-term debt  $   826  $  115  Accounts payable   2,202   2,603  Accrued expenses   2,573   2,791  Deferred income   825   337  Accrued rebates and returns   1,054   1,170  U.S. and foreign income taxes payable  193   167  Dividends payable   606   597  Total Current Liabilities   8,279   7,780  Pension, postretirement and postemployment liabilities   1,882   2,017  Deferred income   4,024   866  U.S. and foreign income taxes payable   648   573  Deferred income taxes   383   107  Other liabilities   475   384  Long-term debt   6,568   5,376  Total Liabilities   22,259   17,103  Bristol-Myers Squibb Company Shareholders’ Equity:  Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and  outstanding 5,117 in 2012 and 5,268 in 2011, liquidation value of $50 per share   -   -  Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both  2012 and 2011   221   220  Capital in excess of par value of stock   2,694   3,114  Accumulated other comprehensive loss   (3,202)  (3,045) Retained earnings   32,733   33,069  Less cost of treasury stock — 570 million common shares in 2012 and 515 million in 2011   (18,823)  (17,402) Total Bristol-Myers Squibb Company Shareholders’ Equity   13,623   15,956  Noncontrolling interest   15   (89) Total Equity   13,638   15,867  Total Liabilities and Equity  $   35,897  $  32,970  Commitments and contingencies (Note 21)  EQUITY The accompanying notes are an integral part of these consolidated financial statements.  31 